The Effect of Teriparatide Compared With Risedronate on Back Pain in Postmenopausal Women With Osteoporotic Vertebral Fractures

CompletadoFase 3ClinicalTrials.gov

ID: NCT00343252Tipo: INTERVENTIONALInicio: 1 de jun de 2006Fin estimado: 1 de jun de 2010

Traducción no disponible, mostrando original

Resumen

The purpose of the study is to determine if daily teriparatide reduces back pain more effectively than weekly risedronate in women with osteoporosis who have chronic back pain due to a spinal bone fracture.

Elegibilidad

Edad mínima: 45 YearsSexo: FEMALE

Criterios de inclusión

Postmenopausal women 45 years or older. No period for at least two years.
History of back pain that started at least 2 months prior to the initial visit (likely due to spinal bone fracture determined by investigator).
Minimum of one moderate spinal bone fracture.
Beginning pain level of at least four on an eleven point scale.
Bone Mineral Density (BMD) must meet criteria
Able to read, understand, and administer self-questionnaires.
Be willing and able to use a pen-injector to deliver the medication.

Criterios de exclusión

Are at increased risk for osteosarcoma.
Have an active or suspected diseases that affects bone metabolism other than osteoporosis.
Participants that already know that they will require procedures to repair their spinal bone fractures.
Abnormal values of certain lab tests.
Anything that would make it difficult to determine if the back pain was due to the fracture.
Poor medical or psychiatric condition.
Alcohol or drug abuse within a year of the study start.
Certain malignant neoplasms in the 5 years prior to enrollment.
Active liver disease or clinical jaundice.
Significantly impaired renal function.
History of nephrolithiasis or urolithiasis within 2 years prior to enrollment.
Known contraindication or intolerance to risedronate and/or teriparatide therapy.
Treatment with oral strontium or certain therapeutic doses of fluoride.

Intervenciones

drug

teriparatide

20 ug/day, subcutaneous, 18 months

drug

risedronate

35 mg/once weekly, oral, 18 months

drug

placebo

once weekly, oral, 18 months

drug

placebo

daily, subcutaneous, 18 months

Ubicaciones

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Buenos Aires, Argentina

Patrocinadores

PrincipalEli Lilly and Company

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

The Effect of Teriparatide Compared With Risedronate on B... | EligiMed